S3 E11 - Self-monitoring BP in pregnancy, ezetimibe or PCSK9 inhibitors for CVD risk & a treatment for alopecia! Plus interview with Aarti Bansal & Veena Aggarwal on Improving Asthma Care & Sustainability in the NHS | NB Medical
 

S3 E11 - Self-monitoring BP in pregnancy, ezetimibe or PCSK9 inhibitors for CVD risk & a treatment for alopecia! Plus interview with Aarti Bansal & Veena Aggarwal on Improving Asthma Care & Sustainability in the NHS

NO
PHARMACEUTICAL INFLUENCE
NO PHARMACEUTICAL INFLUENCE
6th May 2022

If you are having difficulties listening to this Podcast, try to play this episode in Spotify

In the latest Hot Topics podcast from NB Medical Dr Neal Tucker discusses the latest research important in primary care and interviews two experts in improving asthma care and sustainable healthcare.

In new research we examine:

  •  The role of self-monitoring of BP in women with hypertension or higher risk of pre-eclampsia - does it provide early detection?
  • Do ezetimibe and PCSK9 inhibitor provide additional real-world benefits over statins alone? Which is best?
  • Can an oral biological agent, baricitinib, provide some hope for patients with severe alopecia?

We are also joined by Dr Aarti Bansal and Dr Veena Aggarwal to talk about improving asthma care with a new Asthma Toolkit from Greener Practice and healthcare sustainability in the UK. Why are our asthma outcomes poor? Can simple measures improve care? What is the NHS doing to help primary care reduce its carbon footprint?

If you want more join us for our FREE NB Clinic on Tuesday 17th May, 8pm, for Improving Asthma Care and Thinking Green.

Resources

Greener Practice Asthma Toolkit

JAMA Self-monitoring of BP in Pregnancy

BMJ Ezetimibe and PCSK9 inhibitors for Reducing CVD Risk: network meta-analysis

BMJ Lipid-lowering medication Rapid Recommendations

NEJM Baricitinib for Alopecia

Faculty of Medical Leadership and Management Fellowship webpage

BMJ Open Cost of Switching Asthma Inhalers


Join us at one of our upcoming courses or live webinars